LianBio (LIANY)
PNK · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Operating Income | -195.6M | -125.4M |
| Net Income | -196.3M | -110.3M |
| Diluted EPS | $-5.71 | $-1.02 |